This study will consist of a number of arms (sub-studies), each evaluating the efficacy, safety, and tolerability of a specific agent or combination. This study will open with 2 arms (Arms A and B), and additional arms may open, provided there is compelling rationale for the combination and safe and tolerable doses and schedules have been determined from ongoing Phase I studies. There are 2 pre-defined arms: